FDA Gives Guidance on Developing Treatments for Fabry Disease

News
Article

The guidance discusses clinical trial design features that can support approval of treatments of Fabry disease.

FDA published guidance on August 7, 2019 in support of the development of treatments for Fabry disease, a rare lysosomal storage disorder that causes gastrointestinal symptoms, slowly progressive organ damage, and early mortality. The guidance provides information on clinical trial design including patient eligibility criteria and efficacy endpoints.

According to FDA, Fabry disease is “a rare, X-linked, slowly progressive, lysosomal storage disorder caused by pathogenic variants (disease-causing mutations) in the galactosidase alpha (GLA) gene resulting in absent or deficient activity of the lysosomal enzyme α-galactosidase A (α-Gal A). The α-Gal A enzyme breaks down glycosphingolipids within lysosomes. α-Gal A deficient activity leads to progressive intralysosomal accumulation of the undegraded substrate globotriaosylceramide (GL-3, also known as Gb3), a glycosphingolipid.” The disease affects both males and females despite being X-linked; although, males experience the most severe symptoms.  

Source: FDA

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content